MIMESIS is an innovative startup and SpinOff of the University of Catania that applies computational models to the pharmaceutical/nutraceutical sector, allowing the simulation of phenomena of a structural-chemical-biological nature.
Mimesis offers the first generation of “In Silico” solutions to the biomedical industry and pharmaceutical companies to reduce time and costs in the research and development process of medicinal products.
Mimesis cares about ethics since the solutions adopted do not require the use of humans, leading to a potential reduction of the number of patients who take part in clinical studies.
The estimated cost required for the approval of a new drug by regulatory agencies (EMA and FDA) varies between 2 and 3 billion dollars and it takes at least 10 years before the drug arrives on the market.
